OpenAI acquires Orchestra Bio
23d
- Published
- Collected
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
overfeed.news indexes and links. We publish a short excerpt — the full article stays at OpenAI News.
More from OpenAI News
Log in to follow this source
How Amplitude ships product improvements in 1–2 days with OpenAI
Built primarily on OpenAI models, Amplitude’s proactive product agent, Wave, identifies what to build, helps teams ship changes with coding agents, and measures the impact.
Holiday Extras is rethinking what it can build with Codex
With Codex, Holiday Extras is turning customer expertise into better apps, higher booking conversion and new possibilities for growth.
Supporting research on AI and children’s safety
OpenAI commits $2 million to research on AI and children’s safety. The work supports shared tools to measure risks and opportunities for young people.
Gilbert + Tobin rethinks the business of law with AI
A conversation with Sam Nickless, Partner and Chief Executive Officer at Gilbert + Tobin.